Zeitschriftenartikel zum Thema „Drug-sparing regimen“
Geben Sie eine Quelle nach APA, MLA, Chicago, Harvard und anderen Zitierweisen an
Machen Sie sich mit Top-50 Zeitschriftenartikel für die Forschung zum Thema "Drug-sparing regimen" bekannt.
Neben jedem Werk im Literaturverzeichnis ist die Option "Zur Bibliographie hinzufügen" verfügbar. Nutzen Sie sie, wird Ihre bibliographische Angabe des gewählten Werkes nach der nötigen Zitierweise (APA, MLA, Harvard, Chicago, Vancouver usw.) automatisch gestaltet.
Sie können auch den vollen Text der wissenschaftlichen Publikation im PDF-Format herunterladen und eine Online-Annotation der Arbeit lesen, wenn die relevanten Parameter in den Metadaten verfügbar sind.
Sehen Sie die Zeitschriftenartikel für verschiedene Spezialgebieten durch und erstellen Sie Ihre Bibliographie auf korrekte Weise.
Rosa, Rossana, Jose F. Suarez, Marco A. Lorio, Michele I. Morris, Lilian M. Abbo, Jacques Simkins, Giselle Guerra et al. „Impact of antiretroviral therapy on clinical outcomes in HIV+ kidney transplant recipients: Review of 58 cases“. F1000Research 5 (21.12.2016): 2893. http://dx.doi.org/10.12688/f1000research.10414.1.
Der volle Inhalt der QuelleDutta, Noton K., Abdullah Alsultan, Thomas J. Gniadek, Deborah A. Belchis, Michael L. Pinn, Khisimuzi E. Mdluli, Eric L. Nuermberger, Charles A. Peloquin und Petros C. Karakousis. „Potent Rifamycin-Sparing Regimen Cures Guinea Pig Tuberculosis as Rapidly as the Standard Regimen“. Antimicrobial Agents and Chemotherapy 57, Nr. 8 (03.06.2013): 3910–16. http://dx.doi.org/10.1128/aac.00761-13.
Der volle Inhalt der QuelleRuzicka, Daniel J., Mayuko Kamakura, Naho Kuroishi, Nobuyuki Oshima, Miyuki Yamatani, Jingbo Yi, Bruce Crawford, Kunihisa Tsukada und Shinichi Oka. „Characteristics of 2-drug regimen users living with HIV-1 in a real-world setting: A large-scale medical claim database analysis in Japan“. PLOS ONE 17, Nr. 6 (14.06.2022): e0269779. http://dx.doi.org/10.1371/journal.pone.0269779.
Der volle Inhalt der QuelleMaggiolo, Franco, Nicola Gianotti, Laura Comi, Elisa Di Filippo, Laura Fumagalli, Silvia Nozza, Laura Galli, Daniela Valenti, Marco Rizzi und Antonella Castagna. „Rilpivirine plus cobicistat-boosted darunavir as alternative to standard three-drug therapy in HIV-infected, virologically suppressed subjects: Final results of the PROBE 2 trial“. Antiviral Therapy 26, Nr. 3-5 (Mai 2021): 51–57. http://dx.doi.org/10.1177/13596535211042226.
Der volle Inhalt der QuelleSleeper, Rebecca B. „Antipsychotic Dose-Sparing Effect with Addition of Memantine“. Annals of Pharmacotherapy 39, Nr. 9 (September 2005): 1573–76. http://dx.doi.org/10.1345/aph.1g207.
Der volle Inhalt der QuelleTiberi, Simon, Marie-Christine Payen, Giovanni Sotgiu, Lia D'Ambrosio, Valentina Alarcon Guizado, Jan Willem Alffenaar, Marcos Abdo Arbex et al. „Effectiveness and safety of meropenem/clavulanate-containing regimens in the treatment of MDR- and XDR-TB“. European Respiratory Journal 47, Nr. 4 (10.03.2016): 1235–43. http://dx.doi.org/10.1183/13993003.02146-2015.
Der volle Inhalt der QuelleFischl, Margaret A., Ann C. Collier, A. Lisa Mukherjee, Judith E. Feinberg, Lisa M. Demeter, Pablo Tebas, Marina Giuliano et al. „Randomized open-label trial of two simplified, class-sparing regimens following a first suppressive three or four-drug regimen“. AIDS 21, Nr. 3 (Januar 2007): 325–33. http://dx.doi.org/10.1097/qad.0b013e328011ddfa.
Der volle Inhalt der QuelleKaroney, Mercy Jelagat, Mathew Kirtptonui Koech, Evangeline Wawira Njiru und Willis Dixon Owino Ong’or. „Proximal tubular renal dysfunction among HIV infected patients on Tenofovir versus Tenofovir sparing regimen in western Kenya“. PLOS ONE 17, Nr. 9 (15.09.2022): e0273183. http://dx.doi.org/10.1371/journal.pone.0273183.
Der volle Inhalt der QuelleStürmer, Martin, Schlomo Staszewski und Hans Wilhelm Doerr. „Quadruple Nucleoside Therapy with Zidovudine, Lamivudine, Abacavir and Tenofovir in the Treatment of HIV“. Antiviral Therapy 12, Nr. 5 (Juli 2007): 695–704. http://dx.doi.org/10.1177/135965350701200514.
Der volle Inhalt der QuelleKovalskaya, Galina N., Dina Y. Zhukova und Ekaterina N. Mikhalevich. „Interaction of Drugs Used for the Treatment of Cardiovascular Diseases“. Acta Biomedica Scientifica 4, Nr. 1 (04.04.2019): 36–42. http://dx.doi.org/10.29413/abs.2019-4.1.6.
Der volle Inhalt der QuelleDwyer, Dominic E., Cassy Workman, Gillian Hales, Janaki Amin, David Cooper, John Miller und Sean Emery. „Enfuvirtide in HIV-1-Infected Individuals Changing Therapy to A Nucleoside Reverse Transcriptase Inhibitor Sparing Regimen: The Alliance Study“. Antiviral Therapy 11, Nr. 4 (01.05.2005): 409–19. http://dx.doi.org/10.1177/135965350601100406.
Der volle Inhalt der QuelleRabin, Bradford C., Kristina Reid, Tian-Zhi Guo, Eva Gustafsson, Chousheng Zhang und Mervyn Maze. „Sympatholytic and Minimum Anesthetic Concentration-sparing Responses are Preserved in Rats Rendered Tolerant to the Hypnotic and Analgesic Action of Dexmedetomidine, a Selective α2-adrenergic Agonist“. Anesthesiology 85, Nr. 3 (01.09.1996): 565–73. http://dx.doi.org/10.1097/00000542-199609000-00016.
Der volle Inhalt der QuelleLewis, David A. „New treatment options for Neisseria gonorrhoeae in the era of emerging antimicrobial resistance“. Sexual Health 16, Nr. 5 (2019): 449. http://dx.doi.org/10.1071/sh19034.
Der volle Inhalt der QuelleAutar, Reshma S., Mark A. Boyd, Ferdinand WMN Wit, Kiat Ruxrungtham, Jongkol Sankote, Joep MA Lange, David A. Cooper, Praphan Phanuphak, David M. Burger und Peter Reiss. „Relationships between Drug Exposure, Changes in Metabolic Parameters and Body Fat in HIV-Infected Patients Switched to a Nucleoside Sparing Regimen“. Antiviral Therapy 12, Nr. 8 (November 2007): 1265–72. http://dx.doi.org/10.1177/135965350701200813.
Der volle Inhalt der QuelleBrugière, Olivier, Alexandre Vallée, Quentin Raimbourg, Marie-Noelle Peraldi, Sylvie Colin de Verdière, Laurence Beaumont, Abdulmonem Hamid et al. „Conversion to belatacept after lung transplantation: Report of 10 cases“. PLOS ONE 18, Nr. 3 (15.03.2023): e0281492. http://dx.doi.org/10.1371/journal.pone.0281492.
Der volle Inhalt der QuelleSultan, Mamoona, Adeena Khan, Syed Shahid Habib und Dheyab Abdulsalam. „Unique clinical spectrum with distinguishing diagnostic features in Vogt-Koyanagi-Harada syndrome“. BMJ Case Reports 12, Nr. 12 (Dezember 2019): e231397. http://dx.doi.org/10.1136/bcr-2019-231397.
Der volle Inhalt der QuelleDelyagin, Wassili M., und Inna V. Lukjanova. „Heart failure in children and adolescents (high yield topics for primary care pediatrician)“. Pediatrics. Consilium Medicum, Nr. 3 (15.09.2021): 277–84. http://dx.doi.org/10.26442/26586630.2021.3.200998.
Der volle Inhalt der QuelleHong, H., D. W. Dowdy, K. E. Dooley, H. W. Francis, C. Budhathoki, H.-R. Han und J. E. Farley. „Risk of hearing loss among multidrug-resistant tuberculosis patients according to cumulative aminoglycoside dose“. International Journal of Tuberculosis and Lung Disease 24, Nr. 1 (01.01.2020): 65–72. http://dx.doi.org/10.5588/ijtld.19.0062.
Der volle Inhalt der QuelleKast, Richard E., Marc-Eric Halatsch und Rafael Rosell. „OPALS: A New Osimertinib Adjunctive Treatment of Lung Adenocarcinoma or Glioblastoma Using Five Repurposed Drugs“. Cells 10, Nr. 5 (10.05.2021): 1148. http://dx.doi.org/10.3390/cells10051148.
Der volle Inhalt der QuelleTotiger, Tulasigeri M., Anirban Ghoshal, Jenna Zabroski, Anya Sondhi, Saanvi Bucha, Jacob Jahn, Yangbo Feng und Justin Taylor. „Targeted Therapy Development in Acute Myeloid Leukemia“. Biomedicines 11, Nr. 2 (20.02.2023): 641. http://dx.doi.org/10.3390/biomedicines11020641.
Der volle Inhalt der QuelleEisbruch, Avraham, John M. Robertson, Carolyn M. Johnston, Joseph Tworek, Kevin R. Reynolds, James A. Roberts und Theodore S. Lawrence. „Bromodeoxyuridine Alternating With Radiation for Advanced Uterine Cervix Cancer: A Phase I and Drug Incorporation Study“. Journal of Clinical Oncology 17, Nr. 1 (Januar 1999): 31. http://dx.doi.org/10.1200/jco.1999.17.1.31.
Der volle Inhalt der QuelleKim, You Sun. „Treatment of inflammatory bowel diseases: focusing on 5-aminosalicylates and immunomodulators“. Journal of the Korean Medical Association 64, Nr. 9 (10.09.2021): 596–604. http://dx.doi.org/10.5124/jkma.2021.64.9.596.
Der volle Inhalt der QuelleSher, Taimur, Kena C. Miller, Sikander Ailawadhi, Debbie Manfredi, Margaret Wood, Wei Tan, Gregory Wilding et al. „Bortezomib in Combination with Pegylated Liposomal Doxorubicin and Thalidomide (VDT), An Effective Steroid Independent Regimen for Previously Untreated Multiple Myeloma Patients: Final Result of a Phase II Study.“ Blood 114, Nr. 22 (20.11.2009): 618. http://dx.doi.org/10.1182/blood.v114.22.618.618.
Der volle Inhalt der QuelleLaw, Lisa Y., Ryan Stevenson, Gwendolyn Ho, Bijay Nair, Asakura Laura und Antoine Sayegh. „Venetoclax-Based Regimen for Treatment of Patients with Acute Myeloid Leukemia in Community Based Practices“. Blood 134, Supplement_1 (13.11.2019): 5081. http://dx.doi.org/10.1182/blood-2019-121816.
Der volle Inhalt der QuelleHorvath, Lena, und Andreas Pircher. „ASCO 2020 non-small lung cancer (NSCLC) personal highlights“. memo - Magazine of European Medical Oncology 14, Nr. 1 (13.01.2021): 66–69. http://dx.doi.org/10.1007/s12254-020-00673-2.
Der volle Inhalt der QuelleFinn, Jonathan D., Patricia Favaro, J. Fraser Wright, Federico Mingozzi, Katherine A. High und Valder R. Arruda. „Rabbit Anti-Thymocyte Globulin (rATG) Administrated Concomitantly with Liver Delivery of AAV2-hFIX Can Promote Inhibitor Formation In Rhesus Macaques.“ Blood 116, Nr. 21 (19.11.2010): 3765. http://dx.doi.org/10.1182/blood.v116.21.3765.3765.
Der volle Inhalt der QuelleDybkær, Karen, Hanne Due, Rasmus Froberg Brøndum, Ken H. Young und Martin Bøgsted. „Addition of Drug-Response Specific Micro-RNAs to the International Prognostic Index Improves Prognostic Stratification of GCB-DLBCL Patients Treated with R-CHOP“. Blood 134, Supplement_1 (13.11.2019): 1623. http://dx.doi.org/10.1182/blood-2019-122351.
Der volle Inhalt der QuelleSoon, Gaik H., Ping Shen, Eu-Leong Yong, Paul Pham, Charles Flexner und Lawrence Lee. „Pharmacokinetics of Darunavir at 900 Milligrams and Ritonavir at 100 Milligrams Once Daily when Coadministered with Efavirenz at 600 Milligrams Once Daily in Healthy Volunteers“. Antimicrobial Agents and Chemotherapy 54, Nr. 7 (12.04.2010): 2775–80. http://dx.doi.org/10.1128/aac.01564-09.
Der volle Inhalt der QuelleNg, Loke, Yeo, Chng und Tan. „A Meta-Analysis of the Utility of Preoperative Intravenous Paracetamol for Post-Caesarean Analgesia“. Medicina 55, Nr. 8 (31.07.2019): 424. http://dx.doi.org/10.3390/medicina55080424.
Der volle Inhalt der QuelleJeny, Florence, Hilario Nunes und Dominique Valeyre. „Current Medical Therapy for Sarcoidosis“. Seminars in Respiratory and Critical Care Medicine 38, Nr. 04 (27.07.2017): 523–31. http://dx.doi.org/10.1055/s-0037-1604032.
Der volle Inhalt der QuelleS., Sivakumar, und Banupriya K. „Monitoring of adverse drug reactions caused by methotrexate at the dermatology department of a tertiary care centre“. International Journal of Research in Dermatology 3, Nr. 3 (24.08.2017): 389. http://dx.doi.org/10.18203/issn.2455-4529.intjresdermatol20173078.
Der volle Inhalt der QuelleLauretti, Gabriela R., Izabel C. P. R. Lima, Marlene P. Reis, Wiliam A. Prado und Newton L. Pereira. „Oral Ketamine and Transdermal Nitroglycerin as Analgesic Adjuvants to Oral Morphine Therapy for Cancer Pain Management“. Anesthesiology 90, Nr. 6 (01.06.1999): 1528–33. http://dx.doi.org/10.1097/00000542-199906000-00005.
Der volle Inhalt der QuelleGandola, L., M. Nantron, A. Marchianò, A. Pession, P. Indolfi, A. Di Cataldo, P. Collini, G. Arcamone, F. Fossati Bellani und F. Spreafico. „Outcome in stage IV Wilms tumor treated according to the Associazione Italiana Ematologia Oncologia Pediatrica (AIEOP) trials“. Journal of Clinical Oncology 27, Nr. 15_suppl (20.05.2009): 10031. http://dx.doi.org/10.1200/jco.2009.27.15_suppl.10031.
Der volle Inhalt der QuelleMironov, S. P., M. B. Cykunov, G. M. Burmakova und S. V. Andreev. „Lumbosacral pain in athletes and ballet dancers: spondylolysis and spondylolisthesis. Conservative treatment“. N.N. Priorov Journal of Traumatology and Orthopedics 27, Nr. 1 (01.04.2020): 11–18. http://dx.doi.org/10.17816/vto202027111-18.
Der volle Inhalt der QuellePei, Xin-Yan, Michael W. Sanderson, Leena E. Youssefian, Jessica Felthousen, Lora B. Kramer, Yun Dai und Steven Grant. „Bcl-2 Antagonism Potentiates MEK1/2/Chk1 Inhibitor Lethality in Multiple Myeloma Cells Overexpressing Bcl-2 through a Stat3-Dependent Mechanism“. Blood 124, Nr. 21 (06.12.2014): 4763. http://dx.doi.org/10.1182/blood.v124.21.4763.4763.
Der volle Inhalt der QuelleWinkler, K., G. Beron, G. Delling, U. Heise, H. Kabisch, C. Purfürst, J. Berger, J. Ritter, H. Jürgens und V. Gerein. „Neoadjuvant chemotherapy of osteosarcoma: results of a randomized cooperative trial (COSS-82) with salvage chemotherapy based on histological tumor response.“ Journal of Clinical Oncology 6, Nr. 2 (Februar 1988): 329–37. http://dx.doi.org/10.1200/jco.1988.6.2.329.
Der volle Inhalt der Quellevan der Lee, Miranda M. C., Tanja van Achterberg, Kaylee Hersmus, Annet Brouwers-Vos, Monique van der Vleuten, Maurien Pruis, Wendy Kappers et al. „Abstract 3129: BYON4413, an in vivo active CD123-targeting antibody-drug conjugate, combines effectively with azacitidine and venetoclax in acute myeloid leukemia cell lines“. Cancer Research 84, Nr. 6_Supplement (22.03.2024): 3129. http://dx.doi.org/10.1158/1538-7445.am2024-3129.
Der volle Inhalt der QuelleNormant, Emmanuel, Marcelo Lima Ribeiro, Nuria Profitos-Peleja, Pedro Blecua, Diana Reyes-Garau, Juliana Carvalho Santos, Marc Armengol, Miranda Fernández-Serrano, Hari P. Miskin und Gael Roue. „The Ublituximab-Umbralisib (U2) Drug Regimen Potentiates the Activity of the Novel CD47-CD19 Bispecific Antibody, TG-1801, through the Activation of the G Protein-Coupled Receptor EBI2/GPR183“. Blood 138, Supplement 1 (05.11.2021): 1196. http://dx.doi.org/10.1182/blood-2021-150570.
Der volle Inhalt der QuelleLiguori, Nicholas R., Ashley Fss Uruchurtu, Young Lee, Leiqing Zhang, Abbas Abbas, Varun Prabhu, Lanlan Zhou, Christopher J. Azzoli und Wafik S. El-Deiry. „Abstract 4064: Synergistic activity of Lurbinectidin plus ONC201 in SCLC is associated with ATF4, CHOP and pChk1 induction“. Cancer Research 82, Nr. 12_Supplement (15.06.2022): 4064. http://dx.doi.org/10.1158/1538-7445.am2022-4064.
Der volle Inhalt der QuelleLu, Norman, Patricia Soulard, Kay Li, Heather Sadlish, Chris Yates, Xiubin Gu, Ibrahim Kays et al. „Abstract 3306: RGT-M001, a first-in-class small molecule mRNA degrader of the oncogenic transcription factor c-Myb, demonstrated remarkable single agent anti-tumor efficacy in cancer patient-derived xenograft model“. Cancer Research 84, Nr. 6_Supplement (22.03.2024): 3306. http://dx.doi.org/10.1158/1538-7445.am2024-3306.
Der volle Inhalt der QuelleDeisher, Theresa, Margaret Taylor, Arya Ashok, Peter Jarzyna, Yumna Zahid, Stephanie Lee-Diaz, Colleen Rylatt, Kendra Poulin und Vaishnavi Parthasarathy. „AVM0703, a New Treatment Option for Lymphoma Patients“. Blood 134, Supplement_1 (13.11.2019): 5308. http://dx.doi.org/10.1182/blood-2019-128812.
Der volle Inhalt der QuelleHamilton, Erika Paige, Manish R. Patel, Jordi Rodon, David S. Hong, Alison M. Schram, Pasi A. Janne, Patricia LoRusso et al. „Masterkey-01: Phase I/II, open-label multicenter study to assess safety, tolerability, pharmacokinetics, and antitumor activity of BDTX-189, an inhibitor of allosteric ErbB mutations, in patients with advanced solid malignancies.“ Journal of Clinical Oncology 38, Nr. 15_suppl (20.05.2020): TPS3665. http://dx.doi.org/10.1200/jco.2020.38.15_suppl.tps3665.
Der volle Inhalt der QuellediCapua Siegel, David Samuel, Thomas Martin, Michael Wang, Ravi Vij, Andrzej J. Jakubowiak, Sundar Jagannath, Sagar Lonial et al. „Results of PX-171-003-A1, An Open-Label, Single-Arm, Phase 2 (Ph 2) Study of Carfilzomib (CFZ) In Patients (pts) with Relapsed and Refractory Multiple Myeloma (MM)“. Blood 116, Nr. 21 (19.11.2010): 985. http://dx.doi.org/10.1182/blood.v116.21.985.985.
Der volle Inhalt der QuelleMarcelin, A. G., B. Visseaux, M. Wirden, L. Morand-Joubert, C. Soulie, C. Charpentier, B. Masquelier, D. Descamps und V. Calvez. „NRTI-sparing regimens yield higher rates of drug resistance than NRTI-based regimens for HIV-1 treatment“. Journal of Global Antimicrobial Resistance 2, Nr. 2 (Juni 2014): 103–6. http://dx.doi.org/10.1016/j.jgar.2013.12.001.
Der volle Inhalt der QuelleDai, Yun, Shuang Chen, Xin-Yan Pei, Viswanathan Ramakrishnan, Michael Wang, Robert Orlowski, Paul Dent und Steven Grant. „Targeting CDK9 Dramatically Potentiates ABT-737-Induced Apoptosis in Human Multiple Myeloma Cells through a Bim-Dependent Mechanism.“ Blood 114, Nr. 22 (20.11.2009): 297. http://dx.doi.org/10.1182/blood.v114.22.297.297.
Der volle Inhalt der QuelleHoward, Caleigh, Shu Wiley, Wenzhao Dong, Andrea Mendiola, Veronica Partridge, Sara LeMar, Paul Amador et al. „Abstract 335: c-KIT targeted ETBs for cancer therapy and HSC transplant conditioning“. Cancer Research 82, Nr. 12_Supplement (15.06.2022): 335. http://dx.doi.org/10.1158/1538-7445.am2022-335.
Der volle Inhalt der QuellePuoti, Massimo, Alessandro Cozzi-Lepri, Fausto Ancarani, Raffaele Bruno, Silvia Ambu, Teresa Ferraro, Paolo Tundo et al. „The Management of Hepatitis B Virus/HIV-1 Co-Infected Patients Starting Their First Haart Regimen. Treating Two Infections for the Price of One Drug?“ Antiviral Therapy 9, Nr. 5 (Juli 2004): 811–17. http://dx.doi.org/10.1177/135965350400900506.
Der volle Inhalt der QuelleTreon, Steven P., Kirsten Meid, Joshua Gustine, Christopher J. Patterson, Jeffrey V. Matous, Irene M. Ghobrial und Jorge J. Castillo. „Long-Term Outcome of a Prospective Study of Bortezomib, Dexamethasone and Rituximab (BDR) in Previously Untreated, Symptomatic Patients with Waldenstrom's Macroglobulinemia“. Blood 126, Nr. 23 (03.12.2015): 1833. http://dx.doi.org/10.1182/blood.v126.23.1833.1833.
Der volle Inhalt der QuelleYoshizawa, Toshio, Tomoko Yasuhiro, Hideyuki Honda und Kazuhito Kawabata. „ONO-4059—a Potent and Selective Reversible Bruton’s Tyrosine Kinase (Btk) Inhibitor: Single Agent, Twice Daily (BD) Dosing and Dosing with Food Results in Sustained, High Trough Levels of ONO-4059, Translating into 100% Tumour Remission in a TMD-8 Xenograft Model“. Blood 124, Nr. 21 (06.12.2014): 4502. http://dx.doi.org/10.1182/blood.v124.21.4502.4502.
Der volle Inhalt der QuelleWang, C., H. Song, Z. Yu und M. Quan. „AB1009 THE EFFICACY OF TOCILIZUMAB ON THE TREATMENT OF TAKAYASU ARTERITIS IN CHINESE CHILDREN“. Annals of the Rheumatic Diseases 79, Suppl 1 (Juni 2020): 1798.2–1798. http://dx.doi.org/10.1136/annrheumdis-2020-eular.5778.
Der volle Inhalt der Quelle